Navigation Links
New approach to fighting Alzheimer's shows potential in clinical trial
Date:1/6/2010

CAMBRIDGE, Mass. -- In the early stages of Alzheimer's disease, patients typically suffer a major loss of the brain connections necessary for memory and information processing. Now, a combination of nutrients that was developed at MIT has shown the potential to improve memory in Alzheimer's patients by stimulating growth of new brain connections.

In a clinical trial of 225 Alzheimer's patients, researchers found that a cocktail of three naturally occurring nutrients believed to promote growth of those connections, known as synapses, plus other ingredients (B vitamins, phosopholipids and antioxidants), improved verbal memory in patients with mild Alzheimer's.

"If you can increase the number of synapses by enhancing their production, you might to some extent avoid that loss of cognitive ability," says Richard Wurtman, the Cecil H. Green Distinguished Professor of Brain and Cognitive Sciences, who did the basic research that led to the new experimental treatment. He is an author of a paper describing the new results in the journal Alzheimer's and Dementia.

There is currently no cure for Alzheimer's disease, though some medications can slow the progression of the disease. In particular, many U.S. patients take cholinesterase inhibitors, which increase levels of acetylcholine, a neurotransmitter important for learning and memory.

While those treatments target the symptoms of Alzheimer's, Wurtman hopes to attack what he believes is the root cause of the disease: loss of synapses. The three nutrients in his dietary cocktail uridine, choline and the omega-3 fatty acid DHA (all normally present in breast milk) are precursors to the fatty molecules that make up brain cell membranes, which form synapses.

In animal studies, Wurtman has shown that these nutrients boost the number of dendritic spines (small outcroppings of neural membranes). When those spines contact another neuron, a synapse is formed.

Three additional clinical studies in Alzheimer's patients are now underway, one in the United States and two in Europe. Results are expected to be available between 2011 and 2013.

The first clinical study was sponsored by the French company Danone, known in the United States as Dannon; the study was conducted primarily in Europe and was led by Philip Scheltens, director of the Alzheimer Center at Vrije Universiteit Medical Center in Amsterdam. Wurtman and MIT have patented the mixture of nutrients used in the study, and Nutricia Advanced Medical Nutrition, a unit of Danone, holds the exclusive license on the patent.

Patients with mild Alzheimer's drank the cocktail (made in the form of a nutrient drink called Souvenaid, with the collaboration of Danone) or a control beverage daily for 12 weeks. Patients who received the nutrients showed a statistically significant level of improvement compared to control subjects: 40 percent of the treated patients improved performance in a test of verbal memory (memory for words, as opposed to memory of locations or experiences) known as the Wechsler Memory Scale, while 24 percent of patients who received the control drink improved their performance. Among those who received the cocktail, patients with the mildest cases of Alzheimer's showed the most improvement.

The drink appeared to have no effect on patients' performance in another commonly used evaluation for Alzheimer's patients, the ADAS-cog test. Wurtman believes that is because ADAS-cog is a more general assessment that tests for orientation and movement/spatial memory as well as cognition. So in subjects with early Alzheimer's who show principally cognitive changes, more than the 225 subjects in the first study will probably be required to yield significant ADAS-cog changes after Souvenaid. The 500 subjects in the ongoing study in the United States may be sufficient.

John Growdon, a neurologist at Massachusetts General Hospital, says that trying to regrow synapses is an innovative strategy and offers a complementary approach to two other lines of attack in treating Alzheimer's: targeting the amyloid plaques that accumulate in patients' brains, and minimizing the damage done by toxic metabolites that build up in Alzheimer's-affected brains.

"I don't think any one approach has a monopoly, and that's good," Growdon says. "You need to have a lot of different approaches because no one knows what's going to work."

Wurtman believes his approach to Alzheimer's may eventually prove beneficial in treating other diseases. If these nutrients prove to be successful in Alzheimer's patients, "then you can think about other diseases in which there are too few synapses," such as Parkinson's disease, he says. "There are a lot of diseases associated with synapse deficiency."


'/>"/>

Contact: Jennifer Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Clinical trial advances new approach to re-sensitizing breast cancer
2. New approach to emissions makes climate and air quality models more accurate, major study finds
3. NIH launches program to develop innovative approaches to combat obesity
4. Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine
5. New approach to sickle-cell disease shows promise in mice
6. Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu
7. Brandeis studies evaluate visionary approach to improving eyesight
8. TMJ and Chiropractic Care: An Overall Wellness Approach
9. Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR
10. Dallas Facial Plastic Surgeon Publishes Cutting-Edge Novel Approach To Facelift Technique
11. Avizents New TeamCOMP Approach Helps Ensure Lower Workers Comp Costs and Faster Claims Resolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 2017 , ... Watch the video about the Revolution ... Organic Consumers Association, National Health Freedom Action, March Against Monsanto, The National Vaccine ... Moms Across America, Freedom and Ethics Alliance and the Vaccine Injury Awareness League ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main cause of ... to the stuff. The season for grass pollen runs from May to July each year; ... hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... DES MOINES, Iowa , March 29, 2017 ... Iowa Lt. Gov. Kim Reynolds , Department of Public ... Control Policy Director Steve Lukan in announcing the ... at all CVS Pharmacy locations in Iowa.  CVS Health has ... that allows CVS Pharmacy to expand access to ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
Breaking Medicine Technology: